Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation

J Thorac Oncol. 2008 Apr;3(4):452-3. doi: 10.1097/JTO.0b013e318169e341.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Bronchiolo-Alveolar / drug therapy*
  • Adenocarcinoma, Bronchiolo-Alveolar / genetics*
  • Adenocarcinoma, Bronchiolo-Alveolar / secondary
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics*
  • Gemcitabine
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / metabolism
  • Remission Induction
  • Tomography Scanners, X-Ray Computed

Substances

  • Deoxycytidine
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Cisplatin
  • Gemcitabine